Sanofi call-rate KPIs: briefing email breached Clause 15.9 and high standards (AUTH/2947/3/17)

📅 2017 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2947/3/17
PartiesAnonymous v Sanofi
IssueRepresentatives’ call rates / KPI communications
Applicable Code year2016
Complaint received22 March 2017
Case completed14 July 2017
AppealNo appeal
Breach clausesClause 9.1; Clause 15.9
No breach clausesClause 15.1; Clause 15.4; Clause 15.9 (training materials)
Key evidence referencedRedacted manager email dated 16 January 2017 (“Business Reviews – Focus and Action 2017”); certified 2016/2017 training/briefing materials
SanctionsUndertaking received (additional sanctions: Not stated)

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous (contactable) complainant (appearing to be a Sanofi employee) alleged Sanofi set the same call-rate expectations despite widely varying target customer numbers (eg, 30 vs 120), making the required frequency unrealistic in some territories.
  • The complainant alleged management pressure to bring appointments forward and to maintain activity even where Clause 15.4 limits would restrict visits, supported by weekly activity reporting and potential performance plans/disciplinary consequences.
  • The complainant also alleged insufficient training/refreshers on a “heritage product” while representatives could still be bonused.
  • The complainant provided a redacted email (“Business Reviews – Focus and Action 2017”, dated 16 January 2017) referencing expected contacts per day and minimum frequency (including “8 contacts” with hospital doctors and nurses).
  • Sanofi said call rates were part of performance management (15% of measures) but not part of the sales incentive bonus; it provided certified 2016/2017 briefing materials and described training provided (including Lantus eLearning and optional refresher webinar).
⚖️

Outcome

  • No breach of Clause 15.4 (Panel not satisfied, on balance of probabilities, that representatives over-called health professionals).
  • No breach of Clause 15.1 (complainant did not prove lack of training for the unnamed “heritage product”).
  • No breach of Clause 15.9 in relation to the certified 2016/2017 training materials (Panel said they could have been clearer but did not advocate action likely to lead to a breach).
  • Breach of Clause 15.9 in relation to the 16 January 2017 briefing email (email pushed increased contact rate/frequency but was silent on relevant Code requirements and could not rely on training materials).
  • Breach of Clause 9.1 (high standards) as a consequence of the Clause 15.9 breach.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training